Protein-Antibody Conjugates (PACs): A Major Breakthrough in Cancer Research
Recently, a team of scientists from the University of Massachusetts (U.S.) engineered a nanoparticle that has the potential to revolutionize treatment of ailments like cancer and many other incurable diseases.
- This new research combines two different approaches to drug delivery - biologics and antibody-drug conjugates (ADCs) - to produce nanoparticles called protein-antibody conjugates (PACs) that can be used for precise and effective targeted drug delivery to the specific affected cells.
Biologics
- Biologics are products isolated from various natural sources - human, animal, or microorganisms and represent a promising approach to drug delivery.
- Biologics can be composed of proteins, sugars, or nucleic acids ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Wastewater Surveillance: A Game-Changer for Public Health in India
- 2 2025 SCO Summit: A Call for Global Balance and Reform
- 3 Radioactive Pollution in Punjab: Groundwater at Risk
- 4 AI in Courts: Efficiency Tool or Risk to Judicial Reasoning?
- 5 Water Management & Conservation: The Role of Modern Technology
- 6 Biochar: Scalable Solution for Durable Carbon Removal
- 7 Trade Tensions Rise: Indian Exports Face 50% US Tariff
- 8 Harnessing AI for Climate Action: India’s Path to Global Leadership
- 9 India Achieves 20% Ethanol Blending Target: Milestone on the Path to Sustainability
- 10 Toxic Trails: Growing Menace of Heavy Metal Pollution in India
